Atara Biotherapeutics, Inc.
75.0M
$84.53M
6.94
$2.61
No price alerts set. Add an alert to get notified!
6.94
-5.89
$2.61
-84.90%
27.07%
29.69%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
CLNN
Clene Inc.
|
$7.39 | 3.21% | -2.78 | $73.90M | -1.23 |
|
CNTX
Context Therapeutics Inc.
|
$2.33 | -3.32% | -5.51 | $214.08M | 0.01 |
|
COYA
Coya Therapeutics, Inc.
|
$4.20 | -0.94% | -3.31 | $70.26M | 0.00 |
|
CSBR
Champions Oncology, Inc.
|
$5.99 | 0.17% | -36.97 | $83.18M | 1.17 |
|
IFRX
InflaRx N.V.
|
$2.65 | 6.00% | -3.46 | $191.58M | 0.02 |
|
MGNX
MacroGenics, Inc.
|
$2.94 | -2.33% | -2.49 | $186.87M | 1.92 |
|
ORMP
Oramed Pharmaceuticals Inc.
|
$3.91 | -0.26% | 2.15 | $158.14M | 0.00 |
|
OVID
Ovid Therapeutics Inc.
|
$2.73 | -1.80% | -12.80 | $360.04M | 0.10 |
|
STRO
Sutro Biopharma, Inc.
|
$39.83 | 5.68% | -1.79 | $338.47M | -1.78 |
|
STTK
Shattuck Labs, Inc.
|
$6.26 | -6.29% | -14.09 | $299.87M | 0.02 |
* Peer stocks are selected based on market capitalization and sector
$19.15
$3.92
$0.00
0.00%
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
